0001079973-23-001553.txt : 20231113 0001079973-23-001553.hdr.sgml : 20231113 20231113161526 ACCESSION NUMBER: 0001079973-23-001553 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nemaura Medical Inc. CENTRAL INDEX KEY: 0001602078 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 465027260 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38355 FILM NUMBER: 231398931 BUSINESS ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 BUSINESS PHONE: 44-1509-222-912 MAIL ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 8-K 1 nmra_8k.htm FORM 8-K
false 0001602078 0001602078 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): November 13, 2023

NEMAURA MEDICAL INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355

  

46-5027260

(Commission File Number)   (IRS Employer Identification No.)

 

57 West 57th Street

Manhattan, NY

10019

(Address of principal executive offices) (Zip Code)
     
Registrant’s telephone number, including area code:  

+1 (646) 416-8000

 

N/A

(Former name or former address, if changed since last report)

     

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock NMRD The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 Item 2.02. Results of Operations and Financial Condition. 

On November 13, 2023, Nemaura Medical Inc. issued a press release announcing its financial results for the three months ended September 30, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in any website is not a part of this Current Report on Form 8-K.

 

The information included in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

     
Exhibit No.      

Description

   
99.1 Press release of the registrant issued on November 13, 2023.
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

 

 

 

 

 
 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

  NEMAURA MEDICAL INC.
   
  By: /s/ Dewan F.H. Chowdhury
    Dewan F.H. Chowdhury
Chief Executive Officer

 

Date: November 13, 2023 

 

  

 EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Loughborough, England, 13 Nov, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update.

Corporate Highlights:

  1. The Company continued to support its UK licensee with its endeavours to obtain reimbursement for the sensors in the UK.

 

  2. Advanced development of the Company’s BEATdiabetes offering in readiness for a commercial launch in due course.

  

  3. Continued development of its consumer metabolic health platform and potential deployment as a bolt-on service into existing metabolic and wellness programs or to support a direct-to-consumer offering.

 

  4. Received approval from the Saudi Arabia Food and Drug Agency for marketing of sugarBEAT in the Kingdom of Saudi Arabia (KSA), with support from the Company’s licensee in the region, TP MENA.

 

  5. Continued trials of the Company’s pre-diabetes and consumer metabolic health program with the UK National Health Service, the results from which are expected to support the launch of the program in various territories.

 

Financial Summary:

Research and development (“R&D”) expenses were $491,803 and $257,061 for the three months ended September 30, 2023 and 2022, respectively.

General and administrative expenses were $1,558,742 and $1,369,155 for the three months ended September 30, 2023 and 2022, respectively.

Net loss was $1,203,454 and $3,855,700 for the three months ended September 30, 2023 and 2022, respectively.

Cash and cash equivalents at September 30, 2023 were approximately $4.4m.

 

 
 

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a proposal for a Modular PMA (Premarket Approval Application) application for sugarBEAT® to the U.S. FDA, for its generation II, 24 hour sensor. proBEAT™ is a non-regulated version of sugarBEAT which combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the “FDA”) reserves the right to re-evaluate its decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations Contact:

IR@NemauraMedical.com

 

 EX-101.SCH 3 nmra-20231113.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nmra-20231113_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nmra-20231113_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity File Number 001-38355
Entity Registrant Name NEMAURA MEDICAL INC.
Entity Central Index Key 0001602078
Entity Tax Identification Number 46-5027260
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 57 West 57th Street
Entity Address, City or Town Manhattan
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10019
City Area Code (646)
Local Phone Number 416-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol NMRD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 nmra_8k_htm.xml IDEA: XBRL DOCUMENT 0001602078 2023-11-13 2023-11-13 iso4217:USD shares iso4217:USD shares false 0001602078 8-K 2023-11-13 NEMAURA MEDICAL INC. NV 001-38355 46-5027260 57 West 57th Street Manhattan NY 10019 (646) 416-8000 false false false false Common Stock NMRD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nemauramedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nmra-20231113.xsd nmra-20231113_lab.xml nmra-20231113_pre.xml nmra_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nmra_8k.htm": { "nsprefix": "NMRA", "nsuri": "http://nemauramedical.com/20231113", "dts": { "schema": { "local": [ "nmra-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nmra-20231113_lab.xml" ] }, "presentationLink": { "local": [ "nmra-20231113_pre.xml" ] }, "inline": { "local": [ "nmra_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://nemauramedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "nmra_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "nmra_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001079973-23-001553-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-001553-xbrl.zip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